Diabetes
Conditions
Interventions
Aspirin group (81-100mg/day) 2 years
Cilostazol group (100-200,g/day) 2 years
Sponsors
DAPC Study Steering Committee
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with type 2 diabetes who are suspected of having arteriosclerosis obliterans (ASO)
Exclusion criteria
Exclusion criteria: 1 Patients with type 1 diabetes or secondary diabetes 2 Patients aged under 40 years old, or over 76 years old 3 Patients with severe ASO rated as Fontaine IIb or over 4 Patients with cerebrovascular disorders rated as Grade 4 or over in Modified Rankin Scale (Severe disorder which needs assistance for personal care and walk) 5 Patients with a medical history of angina or myocardial infarction 6 Patients with severe hepatic dysfunction (liver cirrhosis) or renal dysfunction (serum creatinine 1.5mg/dl) 7 Patients with congestive heart failure 8 Patients with bleeding tendency or bleeding 9 Patients with severe hematological abnormality 10 Patients with definite homologousfamilial hypercholesterolemia 11 Patients who have allergies or a medical history of hypersensitivity to the investigational drugs 12 Pregnant or lactating women, or women who wish to become pregnant 13 Others whom the investigator judges inappropriate as subjects for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of maximum and mean intima-media thickness (IMT) in bilateral common carotid artery. | — |
Countries
Japan,Asia(except Japan)
Contacts
Public ContactMunehide Matsuhisa
Osaka University Graduate School of Medicine Department of Internal Medicine and Therapeutics
Outcome results
None listed